Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Ovarian cancer (1)
- Ovarian cancer: successful first line therapy
- Ovarian cancer: the problem
- The problem (1)
- Therapy for ovarian cancer: 1970-2010
- The problem (2)
- Why the failure?
- Ovarian cancer (2)
- Overview
- Cancer cells
- Ovarian tumors made of an homogeneous cell?
- The clone theory
- Heterogeneity (1)
- Heterogeneity (2)
- Are ovarian tumors heterogenous?
- Identification of types of ovarian cancer cells (1)
- Identification of types of ovarian cancer cells (2)
- Identification of types of ovarian cancer cells (3)
- What are the differences?
- Molecular characterization (1)
- Molecular characterization (2)
- Molecular characterization (3)
- CD44+ vs CD44- (1)
- CD44+ vs CD44- (2)
- CD44+ vs CD44- (3)
- CD44+ vs CD44- (4)
- Ovarian tumors are heterogenous
- Molecular characterization (4)
- Isolation of CD44 positive cells
- Injection of CD44+ cells
- In vivo FX pro imaging system
- In vivo imaging (1)
- In vivo imaging (2)
- In vivo imaging (3)
- The distribution of the disease
- Cells heterogeneous & hierarchically organized
- Is there a hierarchy within the tumor?
- Cell differentiation
- Pre and post diefferentiation
- Hierarchy
- Molecular characterization (5)
- Endothelial cells differentiation (1)
- Endothelial cells differentiation (2)
- Endothelial cells differentiation (3)
- Cancer stem cells
- Summary
- EOC stem cells
- Questions
Topics Covered
- Introduction to ovarian cancer
- Past therapies for ovarian cancer and their failure
- Heterogeneity in ovarian tumors
- Identification of types of ovarian cancer cells
- Molecular characterization of ovarian cancer cells
- Hierarchy within the ovarian tumors
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Mor, G. (2019, July 31). Ovarian cancer: molecular characterization [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 6, 2024, from https://doi.org/10.69645/DGGQ1958.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Gil Mor has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Ovarian cancer: molecular characterization
Published on July 31, 2019
25 min
Other Talks in the Series: The Female Reproductive System: from Basic Science to Fertility Treatments
Transcript
Please wait while the transcript is being prepared...
0:00
The subject that I'm going to discuss today is related to "Ovarian Cancer".
My name is Gil Mor and I'm a professor in
the Department of Obstetrics and Gynecology and I am the Director of
the Reproductive Immunology unit at Yale University School of Medicine.
0:22
Ovarian cancer is the leading cause of death from
all the gynecological cancers and the reason is
because it presents with advanced stage in the disease.
It's very difficult to identify the presence of the cancer in
early stages as we will discuss later and unfortunately,
there are no effective new therapies that can treat this terrible killer.
0:50
Ovarian cancer is a successful first-line therapy.
80 percent of the patients respond to the treatment that involves taxol and carboplatin.
So the question is,
what is the contradiction between the high degree of mortality that we
see in ovarian cancer patients and the successful response?
The answer is that even after complete de-bulking and chemotherapy,
1:17
60 percent of the patients will relapse within a year and 80 percent within 5 years,
1:32
and the problem is precisely in the following aspects.
Recurrence is characterized by what we define as chemoresistant disease and second,
the metastasis or carcinomatosis.
That is the spreading of the disease all over the intraperitoneal cavity.